ACT: The MATTERHORN trial showed a 22% reduction in the risk of death with the Imfinzi regimen. How significant is this ...

See Agentic AI in action as it eases site payments manual processes such as Clinical Trial Agreements (CTAs) ingestion and ...

Because the data [are] contextualized, we know who the physicians are [that are] working with the patients we aspire to treat ...

In today’s ACT Brief, we spotlight how new OpenAI collaborations are transforming drug development, how AI is driving smarter site activation in global trials, and how the FDA’s approval of a ...